SG Americas Securities LLC Sells 9,896 Shares of Disc Medicine, Inc. $IRON

SG Americas Securities LLC lessened its stake in shares of Disc Medicine, Inc. (NASDAQ:IRON) by 46.9% during the 1st quarter, HoldingsChannel.com reports. The fund owned 11,226 shares of the company’s stock after selling 9,896 shares during the period. SG Americas Securities LLC’s holdings in Disc Medicine were worth $718,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the stock. ANTIPODES PARTNERS Ltd acquired a new position in shares of Disc Medicine during the 4th quarter worth approximately $33,000. KBC Group NV acquired a new stake in shares of Disc Medicine in the fourth quarter valued at approximately $80,000. Persistent Asset Partners Ltd acquired a new stake in shares of Disc Medicine in the fourth quarter valued at approximately $141,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Disc Medicine by 36.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,834 shares of the company’s stock worth $146,000 after acquiring an additional 490 shares during the period. Finally, Avanza Fonder AB increased its holdings in shares of Disc Medicine by 14.1% during the 4th quarter. Avanza Fonder AB now owns 1,903 shares of the company’s stock worth $151,000 after acquiring an additional 235 shares during the last quarter. 83.70% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Disc Medicine

In other news, CFO Jean M. Franchi sold 6,257 shares of the company’s stock in a transaction on Tuesday, April 14th. The shares were sold at an average price of $69.24, for a total value of $433,234.68. Following the sale, the chief financial officer directly owned 64,333 shares of the company’s stock, valued at approximately $4,454,416.92. This represents a 8.86% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO John D. Quisel sold 34,000 shares of the stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $70.21, for a total transaction of $2,387,140.00. Following the sale, the chief executive officer owned 226,064 shares of the company’s stock, valued at approximately $15,871,953.44. This trade represents a 13.07% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 85,000 shares of company stock worth $5,956,865. Company insiders own 3.76% of the company’s stock.

Disc Medicine Trading Up 3.5%

Shares of IRON stock opened at $79.70 on Tuesday. The stock has a market cap of $3.04 billion, a P/E ratio of -11.96 and a beta of 0.97. Disc Medicine, Inc. has a 1 year low of $40.00 and a 1 year high of $99.50. The company has a current ratio of 24.00, a quick ratio of 24.00 and a debt-to-equity ratio of 0.04. The stock has a 50 day simple moving average of $69.53 and a 200 day simple moving average of $70.18.

Disc Medicine (NASDAQ:IRON) last announced its earnings results on Tuesday, May 5th. The company reported ($1.65) EPS for the quarter, missing the consensus estimate of ($1.62) by ($0.03). On average, research analysts predict that Disc Medicine, Inc. will post -6.74 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have commented on IRON. Wall Street Zen raised shares of Disc Medicine from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. Morgan Stanley increased their price objective on shares of Disc Medicine from $80.00 to $85.00 and gave the company an “overweight” rating in a research report on Monday, June 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Disc Medicine in a report on Monday, April 20th. Finally, Wedbush reaffirmed an “outperform” rating and set a $88.00 target price on shares of Disc Medicine in a report on Wednesday, June 10th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $104.44.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.